Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$114M |
| 2 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$31.3M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$26.4M |
| 4 |
Tyler Technologies
TYL
|
+$25M |
| 5 |
Brown & Brown
BRO
|
+$18.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$249M |
| 2 |
CELG
Celgene Corp
CELG
|
+$231M |
| 3 |
Microsoft
MSFT
|
+$171M |
| 4 |
Alibaba
BABA
|
+$140M |
| 5 |
Amazon
AMZN
|
+$99.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Healthcare | 14.66% |
| 3 | Consumer Discretionary | 11.66% |
| 4 | Communication Services | 10.19% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Arrow Financial
AROW
$721M
| $975K | ﹤0.01% |
29,025
+901
| +3% | +$28.3K |
|
|
BDSI
2152
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $975K | ﹤0.01% |
+154,300
| New | +$907K |
|
2153
Johnson Outdoors
JOUT
$494M
| $974K | ﹤0.01% |
12,700
+400
| +3% | +$26.2K |
|
2154
Smith & Wesson
SWBI
$638M
| $973K | ﹤0.01% |
136,410
+4,424
| +3% | +$27K |
|
|
AXDX
2155
DELISTED
Accelerate Diagnostics
AXDX
| $970K | ﹤0.01% |
5,740
+190
| +3% | +$31.4K |
|
2156
MacroGenics
MGNX
$249M
| $967K | ﹤0.01% |
88,900
+2,700
| +3% | +$26.7K |
|
2157
Phibro Animal Health
PAHC
$1.38B
| $966K | ﹤0.01% |
38,900
+1,100
| +3% | +$25.5K |
|
|
MITT
2158
TPG Mortgage Investment Trust
MITT
$214M
| $965K | ﹤0.01% |
20,867
+434
| +2% | +$20K |
|
2159
Kenon Holdings
KEN
$3.34B
| $964K | ﹤0.01% |
45,182
+5,121
| +13% | +$109K |
|
2160
OrthoPediatrics
KIDS
$633M
| $963K | ﹤0.01% |
20,500
+4,100
| +25% | +$159K |
|
|
GOGL
2161
DELISTED
Golden Ocean Group
GOGL
| $962K | ﹤0.01% |
165,705
+4,637
| +3% | +$26.6K |
|
|
HIBB
2162
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $962K | ﹤0.01% |
34,300
+800
| +2% | +$20.3K |
|
2163
Intellia Therapeutics
NTLA
$1.68B
| $961K | ﹤0.01% |
65,500
+5,500
| +9% | +$76.5K |
|
2164
First Financial Corp
THFF
$967M
| $961K | ﹤0.01% |
21,026
+500
| +2% | +$22.1K |
|
2165
Opko Health
OPK
$1.04B
| $953K | ﹤0.01% |
648,100
+12,900
| +2% | +$21.6K |
|
2166
Camping World
CWH
$655M
| $949K | ﹤0.01% |
64,400
+1,700
| +3% | +$19.2K |
|
2167
OraSure Technologies
OSUR
$268M
| $949K | ﹤0.01% |
118,200
+1,900
| +2% | +$15.4K |
|
2168
Ituran Location and Control
ITRN
$1.04B
| $948K | ﹤0.01% |
37,725
| – | – |
|
|
DO
2169
DELISTED
Diamond Offshore Drilling
DO
| $948K | ﹤0.01% |
131,853
+3,900
| +3% | +$22.7K |
|
2170
Amneal Pharmaceuticals
AMRX
$5.96B
| $946K | ﹤0.01% |
196,300
+25,100
| +15% | +$87.3K |
|
|
WSR
2171
DELISTED
Whitestone REIT
WSR
| $944K | ﹤0.01% |
69,300
+2,700
| +4% | +$37.1K |
|
|
PLYA
2172
DELISTED
Playa Hotels & Resorts
PLYA
| $940K | ﹤0.01% |
111,900
+2,600
| +2% | +$20.2K |
|
|
PETQ
2173
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $937K | ﹤0.01% |
37,400
+1,700
| +5% | +$42.2K |
|
2174
Akebia Therapeutics
AKBA
$240M
| $935K | ﹤0.01% |
147,885
+4,100
| +3% | +$19.5K |
|
2175
Resources Connection
RGP
$144M
| $932K | ﹤0.01% |
57,100
| – | – |
|
Similar funds
Swiss National Bank's Q4 2019 Portfolio in Review
As of Q4 2019, Swiss National Bank held 2,602 positions worth $97.5B, up 3.6% from $94.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Swiss National Bank withdrew a net $3.98B in Q4 2019, closing 96 positions and reducing 725 holdings. Its most notable exit was Celgene Corp, an estimated $231M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in Match Group worth $14.7M.
- Swiss National Bank's largest Q4 2019 buy was Match Group: 179,200 shares worth $14.7M.
- Swiss National Bank added most to Bristol-Myers Squibb in Q4 2019, an estimated $114M increase.
- Swiss National Bank's biggest Q4 2019 reduction was Apple, cutting an estimated $249M.
- Swiss National Bank fully exited Celgene Corp in Q4 2019, selling an estimated $231M.
- Swiss National Bank's ten largest holdings make up 19% of its $97.5B portfolio in Q4 2019.
- Swiss National Bank opened 82 new positions and closed 96 in Q4 2019.
- Swiss National Bank's portfolio value rose 3.6% quarter-over-quarter to $97.5B.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.